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Abstract
Genetic polymorphism and prostate cancer (PC) are the most pernicious and 
recurrently malignancy worldwide. It is the most dominating cause of cancer 
related casualty among men in the US. Asian countries are inflicted with PC at 
an alarming rate though still the prevalence of PC is lower than European and 
American men. Some of the genetic and environmental factors that might play 
a role in PC risk include: age genetic predilection, family history, race/ethnicity, 
lifestyle, and dietary habits and non-dietary environmental risk factors such as 
smoking. Socio-economic factors including economic, scholastic and intellectual 
factors do not, intrinsically seem to straight away influence the risk of acquiring 
PC. Other genetic changes that may support an increased risk of developing PC 
include HPC1, HPC2, HPCX, CAPB, ATM,s HOXB13 and mismatch repair genes. 
PC occurrence rates are highly variable. Almost all PC mortalities are due to meta-
static disease, generally through tumors the progress to be hormone refractory or 
castrate resistant. PC, developing research has acknowledged a number of candi-
date genes and biological pathways associated with PC. Indirect pathways such as 
P13K/AKT signaling pathway is one of most well known alternate pathway in PC 
Vascular endothelial growth factor (VEGF) is widely known to be potent stimula-
tor of angiogenesis. The over expression of EGFR in a very large majority of cases 
is accompanied by the succession of PC, implying that this may play a mechanistic 
role. Numerous occupational factors have been proposed to cause PC. Some of the 
risk factors include; farmers/agricultural workers, pesticides, shift work and flight 
personnel. PC treatment can be done through surgery, radical prostatectomy is 
the main type of surgery. Risks of injury are many – reactions to anesthesia, loss 
of blood, blood clumps in the legs/lungs, injury to surrounding organs, infection 
at the site of surgery and many more. The other treatments are hormone therapy, 
chemotherapy and radio therapy chemotherapy. Chemotherapeutic drugs are 
typically used one at a time for PC such as transurethral resection of prostate 
(TURP). Some of the chemotherapeutic drugs are Docetaxel, Cabazitaxel, 
Mitoxantrone and Estramustine. Among the score of biomarkers being studied, 
numerous markers and techniques deserve awareness and acceptability for both 
patients and urologists in clinical practice.
Keywords: prostate, BRCA2, P13K/AKT signaling pathway, single nucleotide 
polymorphisms (SNPs)
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1. Introduction
Cancer is both genetically and phenotypically sophisticated. Among all the 
cancers known so far, prostate cancer (PC) is the most pernicious and recurrently 
diagnosed malignancy worldwide (after lung cancer), counting 1,414,259 new 
cases (7.3% of all cancer associated diseases) and causing 375,304 deaths (3.8% of 
all deaths caused by cancer in men) in 2020 [1]. It is the second most dominating 
cause of cancer related casualty among men in the United States. Prostate cancer is 
expected to cause 248,530 new cases and 34,130 deaths in the United States in 2021, 
making it the most common cancer among American men [2]. Prostate cancer is 
thought to contain a genetic makeup that includes somatic copy number changes, 
point modifications, structural rearrangements, and chromosomal number differ-
ences [3]. The somatic transformation rate of prostate cancer lies between 1x10−6 
and 2x10−6 which is identical to breast, renal and ovarian cancer [4]. However, in 
addition to somatic genetic alterations, it has been discovered that prostate cancer is 
associated with the loss of tumor suppressor gene activity due to epigenetic changes 
in their expression. Prostatic adenocarcinoma is the most frequent type of prostate 
cancer, accounting for nearly all occurrences. It grows in the cells of the glands that 
produce prostatic fluid. A digital rectal exam (DRE), a prostate-specific antigen 
(PSA) blood test, a prostate biopsy, or a computed tomography (CT) scan are all 
common ways for a clinician to detect prostate cancer [5].
Prostate cancer is categorized as the third highest among cancers of the male 
urinary and reproductive system in China. In Chinese populations, this condi-
tion impairs the quality of life and longevity of men over the age of 50 [6]. India 
presently has a population of over a billion people, with an estimated 1.5 million 
cancer cases reported each year. Asian Indians were diagnosed at an average age 
of 65.9 years (range: 46–86 years). India has a low incidence of prostate cancer. 
However, due to a dearth of prostate cancer screening, the majority of individuals 
are detected at an advanced stage [7]. The percentage of individuals with late-
stage prostate cancer who have both high-grade illness and bone metastases is 65 
percent. African-American men had a greater occurrence rate and a more severe 
kind of prostate cancer than White men. Prostate cancer is currently afflicting 
Asian countries at an alarming rate. Still, the prevalence of prostate cancer in Asian 
men is comparatively lower than European and American men. One reason that is 
endorsed by epidemiologic studies of immigrant populations and by recent somatic 
genomic alteration analysis is due to distinct genetic backgrounds. The etiological 
factors correlated with prostate cancer are still unresolved and ambiguous [8]. 
Variations in social, environmental, and genetic factors are thought to be the cause 
of this disparity. Some of the factors that may influence the risk of prostate cancer 
include:
• Age, genetic predisposition,
• family history
• race/ethnicity
• lifestyle and food habits are all factors to consider.
Although hereditary factors have been suspected to have a role in prostate 
cancer etiology, only a few genetic markers linked to prostate cancer risk have been 
identified. The strongest risk factor is acknowledged to be a hereditary liability [9]. 
Variations in the usage of diagnostic tests are reflected in the incidence rates around 
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the world. The importance of family history in obtaining evidence for major genetic 
determinants in cancer prevalence cannot be overstated. Prostate cancer progres-
sion and progression are influenced by lifestyle and nutritional habits. Future 
research is needed to better understand the interaction of environmental and dias-
pora factors [10]. Prostate cancer is generally asymptomatic at the initial stage and 
may require minimal or no treatment at all. However, the most recurring grievance 
is complications with urination and nocturia. Prostatic hypertrophy causes all of 
the symptoms listed above. Because the axial skeleton is the most prevalent site of 
bone metastatic disease, more advanced stages of the disease may exist with urine 
retention and back pain [11].
Genetics has an important role in the initiation and progression of prostate 
cancer. Tumor biomarkers are used to detect, treat, and diagnose many tumors in 
their early stages. Understanding the genesis and causative risk factors for prostate 
cancer can help to provide some solutions. This can aid in the expansion of signifi-
cant screening and precluding methods for prostate cancer. Currently, no evidence 
supports how to prevent this cancer [12]. A promising understanding of the etiol-
ogy and causative risk components is crucial for understanding cancer prevention. 
This cancer has a complex, multiple etiology, with 42 percent genetic factors and 58 
percent environmental/lifestyle factors estimated to be involved. Prostate cancer is 
a growing threat to Asian men’s health. Although the rate of incidence of prostate 
cancer is far greater in Western cultures (120 per 100,000 in Northern America) 
than in East Asian cultures (less than 10 per 100,000 in Asia), when Asians migrate 
to Western countries, their rate of prostate cancer incidence increases [13]. Prostate 
cancer has all of the criteria of an excellent chemoprevention target illness, includ-
ing a lengthy latency, high incidence, a huge proportion of tumor markers, and 
identifiable preneoplastic lesions.
The increased morbidity and mortality from prostate cancer necessitate the 
implementation of current and effective preventive measures in everyday life. In 
conclusion, no vital known lifestyle or infectious agent is recognized as a risk factor 
for prostate cancer, categorizing it as one of the limited widespread cancers with 
unidentified risk factor [14].
2. Occurrence rates
Prostate cancer occurrence rates are highly variable. Occurrence, stringency, and 
mortality rates vary with ethnicities, geological location, and age. Its risk increases 
with an increase in age with the youngest being least susceptible. Also, this cancer 
is more widespread and invasive in African-Americans [15]. Native Asians, on the 
other hand, have a remarkably low incidence of prostate cancer, which is likely due 
to a combination of environmental and hereditary factors. Prostate cancer has the 
highest occurrence of 83.4% per 1000,000 incidences in Northern Europe, notably 
Ireland, and the lowest occurrence rate in South Central Asia, at 6.3 per 100,000. In 
Asia, however, prostate cancer accounts for only 1–10% of cases, but the incidence 
of occurrence is rapidly increasing [16].
Prostate cancer ranks second (37.5 per 100,000) in nations with a high Human 
Development Index (HDI), and vice versa in countries with a low HDI (11.3 per 
100,000). The highest occurrence rates of prostate cancer are found among black 
men in the United States and the Caribbean, confirming the importance of Western 
African ancestry in controlling prostate cancer risk. The variation in prostate 
cancer incidence rates is mainly due to different prostate cancer diagnostic practices 
globally. In the early 1980s and late 1990s, there was a drastic increase in prostate 
cancer cases in the United States, Australia, and Canada due to which the detection 
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of pre-symptomatic cancer was feasible [17]. The adoption of prostate-specific 
antigen (PSA) testing was a major factor in this. One of the most striking features 
of prostate cancer is the wide range of occurrence rates caused by differences in 
race, geography, or age, as well as variations in environmental factors such as work 
environment, nutrition, and lifestyle, all of which can increase the risk of preco-
cious prostate cancer. Environmental factors are one of the reasons for varied 
incidence rates of different cancers globally [18]. The cause of prostate cancer is 
unknown, even though it is more common in some populations. However, it is clear 
that prostate cancer is a multifaceted illness with various genetic and environmental 
variables contributing to its etiology.
3. Mortality rates
Almost all deaths from prostate cancer are caused by metastatic illness, which 
occurs when tumors become hormone-refractory or castrate-resistant. Prostate 
cancer mortality rates have dropped dramatically in Northern America, Northern, 
and Western Europe, indicating improved treatment and early detection through 
increased screening [19]. The highest mortality rate of prostate cancer is 27.9 per 
100,000 in the Caribbean, with the lowest mortality rate being 3.1 per 100,000 
in South Central Asia. The highest occurrence and mortality rates are found in 
African-American men. As a result, we can speculate that African-American males 
may maintain some genes that are more susceptible to mutations in prostate cancer 
and that these mutations are linked to a more aggressive type of cancer. African-
American men, as well as men with a family history, should be screened at the age 
of 45. Undeniable death is the most important prostate cancer endpoint [20].
4. Genes associated with prostate cancer risk
Developing research has acknowledged a number of candidate genes and 
biological pathways associated with increased susceptibility to cancer. A signifi-
cantly recent direction for scientists to identify genes involved in human disease 
is Genome-wide association studies (GWAS) [21]. This approach looks for tiny 
differences in the genome known as SNPs (single-nucleotide polymorphisms). 
Because genome-wide association studies examine SNPs across the genome, they 
promise a promising technique to research complex, prevalent diseases in which 
numerous genetic variations contribute to a person’s risk. Genome-wide association 
studies provide an enormous approach for the identification of genetic markers cor-
related with prostate cancer risk. Hundreds of thousands of SNPs can be examined 
simultaneously in each analysis [22]. In genome-wide association studies (GWAS), 
case–control surveys, multiple linkage estimations, next-generation sequencing 
(NGS), and admixture mapping studies, several genes and chromosomal areas 
have been identified to be associated with prostate cancer. As more prostate cancer 
risk variations are identified, the cumulative effects of these variants may become 
increasingly important clinically. Unfortunately, attempts at specifying a reliable 
biomarker have thus far proved futile (Table 1) [15–17].
There is a significant role of genetics in prostate cancer that is indicated through 
epidemiological studies. In the advancement and succession of prostate cancer, 
there is an involvement of a heightening number of single nucleotide polymor-
phisms (SNPs). Individual SNPs show a moderate connection with prostate cancer 
risk, but when they are combined, they have a larger, dose-dependent associa-
tion that presently accounts for 30% of prostate cancer family risk. An SNP is a 
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deviation from the predicted nucleotide in a DNA sequence that arises when a single 
nucleotide (A, T, C, or G) in the genome changes [20–24]. SNPs are thought to make 
a significant impact on disease vulnerability. SNPs are simple to find and only exist 
once, making them an ideal biomarker. Because of the growing interest in the role 
of SNPs in prostate cancer progression and succession, a large number of studies on 
SNPs in prostate cancer are being published [25].
Many case–control studies have recognized innumerable single nucleotide poly-
morphisms (SNPs) correlated with prostate cancer but the clinical role of these SNPs 
remains ambiguous. Some SNPs also affect levels of the prostate-secreted proteins, 
prostate-specific antigen (PSA), hexokinase (HK) 2, and β-microseminoprotein 
(β-MSP); prostate cancer risk was also related with some of these SNPs. Numerous 
SNPs associated with prostate cancer affect the role and/or generation of a prostate 
cancer marker. For example, rs198977 in KLK2 may affect hK2 function and decrease 
hK2 levels in blood [26]. The SNP rs10993994 in MSMB reduces levels of β-MSP and 
is correlated with increased levels of PSA in the blood or semen of an active young 
man. The function of cell cycle dysregulation in prostate cancer vulnerability has 
been described via changing the cell’s ability to respond effectively to DNA damage. 
Patients with advanced or metastatic prostate cancer have been reported to exhibit 
modifications in the CDKN2 gene but not in primary tumors (Table 2) [27].







BRCA1 UK and IRELAND 376 Weakly 
validated
Nyberg et al., 2020
BRCA2 UK and IRELAND 447 Validated Nyberg et al., 2020
AR NON-HISPANIC WHITE 226 Validated Ingles et al., 1997
HOXB13 NORTHERN EUROPEAN 3508 Validated Cooney et al., 2016
CYP17A1 TUNISIAN 250 Validated Souiden et al., 2011
SRD5A2 CHINESE 495 Validated Hsing et al., 2001
TLR4 NORTH INDIAN
Asian
398 Validated Singh et al., 2013
HNF1B EUROPEAN AMERICANS, 
JAPANESE and AFRICAN 
AMERICANS
483 Validated Grisanzio et al., 2012
MSMB SOUTHERN CHINESE 
HAN
509 Validated Xu et al., 2010
JAZF1 EUROPEAN 19421 Validated Prokunina-Olsson 
et al., 2010
ESR1 CAUCASIAN 1859 Validated Nicolaiew et al., 2009
(RNase L) HPC1 SWEDISH 2425 Not 
validated
Wiklund et al., 2004
ELAC2/HPC2 AUSTRALIAN 1557 Not 
validated
Severi et al., 2003
MSR1 CHINESE 410 Validated Hsing et al., 2007
PSA JAPANESE 782 Not 
validated
Wang et al., 2003
HPCX ASHKENAZI JEWISH 2230 Validated Agalliu et al., 2010
Table 1. 
Genes associated with prostate cancer.
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The t-allele of MDM2 was found to be the most strongly linked to prostate can-
cer. The presence of at least one copy of the t allele of MDM2 tSNP309g increases 
the risk of advanced prostate cancer. The association of the rs1447295 A allele with 
prostate cancer was reported. However, no substantial relation of the rs6983267 
G allele with prostate cancer patients was recorded. Seven single nucleotide poly-
morphisms (SNPs) on chromosome 17q, 3 SNPs on 17q12, and 4 SNPs on 17q24.3 
are associated with the risk of prostate cancer was recognized in the European 
population by a genome-wide association study (GWAS) [25–28]. Research on 
susceptibility genes is one of the hottest subjects in prostate cancer risk factors. 
Even still, confirming the prostate cancer susceptibility genes has proven difficult. 
In 2007, in a GWAS conducted in the United States based on 3 known risk loci of 







rs6983267 8q24 Caucasians 
and Asians
50854 Identified Li et al., 2015
rs1447295 8q24 Caucasians 
and Asians
50854 Identified Li et al., 2015
rs16901979 8q24 Africans 
Americans
50854 Identified Li et al., 2015
rs138213197 HOXB13 Europeans 9012 Identified Beebe-Dimmer 
et al., 2015
rs4242382 8q24 Asian and 
Caucasian








421 Identified Levin et al., 2008
rs10896449 11q13 European 19395 Identified Chung et al., 2011
rs10486567 7p15.2 Finnish 947 Not 
identified
Chen et al., 2014
rs1938781 11q12 Japanese 5560 Identified Akamatsu et al., 
2012
rs2252004 10q26 Japanese 5560 Identified Akamatsu et al., 
2012








rs12793759 11q13 European 19395 Identified Chung et al., 2011
rs3737559 2p15 Icelander 23205 Identified Gudmundsson 
et al., 2008
rs5945572 Xp11.22 Icelander 23205 Identified Gudmundsson 
et al., 2008
Table 2. 
SNPs associated with prostate cancer.
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prostate cancer, SNPs rs4242382 and rs6983267 on 8q24 and SNP rs4430796 on 17q 
in the hepatocyte nuclear factor 1B (HNF1B) gene, 4 SNPs associated with prostate 
cancer, rs10993994 on chromosome 10 in the microseminoprotein-beta (MSMB) 
gene, rs4962416 on chromosome 10 in the C-terminal binding protein 2 (CTBP2) 
gene, rs10896449 on 11q13, and rs10486567 on chromosome 7 in the juxtaposed 
with another zinc finger protein 1 (JAZF1) gene was observed [29]. Two loci within 
the gene, SNPs rs1799950, and rs3737559, have been associated with early-onset 
prostate cancer and genealogical prostate cancer, respectively.
The steroid SRD5A2 gene, located on chromosome 2p23 is a major gene that 
makes it prone to prostate cancer. Evidence supporting the linkage of this gene 
to prostate cancer is provided [30]. The transformation of testosterone (T) leads 
to dihydrotestosterone (DHT), the most powerful androgen receptor adversary 
in prostate cells by 5α-reductase (5-AR) enzymes (types 1 and 2). Under normal 
physiological conditions, a 5-AR enzyme that is encoded by SRD5A2 is inevitably 
expressed over SRD5A1 in the prostate. Attractive targets for preventing prostate 
cancer advancement are represented by 5-AR enzymes. The hypothetical basis for 
chemoprevention strategies is the inhibition of 5-AR enzymes and the reduction 
of prostate cancer succession in low-risk disease was also lately shown [30–33]. To 
potentially advance cancer growth and proliferation, SRD5A genetic variations 
alter sex-steroid exposure. Further studies are required to fully comprehend the 
influence of functional variations in SRD5A genes in both normal and prostate 
cancer cells.
Androgens are widely known to play a significant role in the progression of 
prostate cancer, even until it reaches advanced stages. In prostate cancer, especially 
castration-resistant prostate cancer, the androgen receptor (AR) plays a critical role 
(CRPC) [34]. Androgen deprivation therapy suppresses hormone-naive prostate 
cancer; however, AR is altered by prostate cancer and adapts for survival at castra-
tion levels of androgen. The AR gene can be found on chromosome X (Xq11–12). 
Shorter glutamine repeats have been linked to increased AR transcriptional activity 
[35]. The role of epithelial AR is to send secretory proteins to the prostate gland, 
such as prostate-specific antigen (PSA), whereas stromal AR is involved in prostate 
development. Most prostate cancers can be suppressed with androgen deprivation 
therapy, however, some high-risk prostate tumors progress to castration-resistant 
prostate cancer, which then thrives under castrated testosterone levels [36]. AR is 
the most frequent anomalous gene in metastatic CRPC. Several mechanisms play 
a fundamental role in the development of metastatic CRPC: Point mutations in 
the androgen receptor, Androgen receptor amplification, Variations of androgen 
biosynthesis, Variations in androgen receptor cofactor in the prostate cancer, and 
Androgen receptor variants [37].
The binding of anti-androgens such as bicalutamide and flutamide to the ligand-
binding domain (LBD) of AR inhibits androgen binding to LBD. In the progres-
sion of prostate cancer to castration-resistant prostate cancer, prostate cancer 
survives and restarts its growth under castration levels of androgen. A second-
generation non-steroidal anti-androgen with greater affinity for the LBD of AR is 
Enzalutamide [38]. Androgens play a critical role in the progression of both normal 
prostate epithelium and stromal prostate cancer, and activation of genes involved in 
androgen metabolism may be linked to an increased prostate cancer risk.
A fundamental regulatory enzyme in the steroidogenic pathway is Cytochrome 
P450 17α-hydroxylase/17,20-lyase (CYP17A1); Both 17α-hydroxylase and 17,20-lyase 
activities are catalyzed by CYP17A1 and it is crucial for the production of both 
androgens and glucocorticoids [39]. CYP17A is a target for the hormonal treat-
ment of prostate cancer. Many recent investigations have found that CYP17A1 is 
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significantly expressed in more than 50% of human prostate carcinomas, indicating 
that cancer cells synthesize androgen intracellularly. The degree of expression was 
directly linked to nuclear expression of the phosphorylated active form of ARs. 
CYP17A1 plays a crucial role in adrenal and intratumoral de novo biosynthesis of 
androgens. Abiraterone is a suppressor of CYP17A1. Current genes of interest that 
have been identified as genealogical tumor suppressor genes and act as biomark-
ers for prostate cancer include RNase L (HPC1, 1q22), MSR1 (8p), ELAC2/HPC2 
(17p11). Pathogenic variations in genes, such as BRCA1, BRCA2, the mismatch 
repair genes, and HOXB13 exchange views on subtle to a mild lifetime risk of 
prostate cancer [40].
In the breast cancer predisposition gene 2 (BRCA2), germline mutations are 
the genetic events known to date that confer the highest risk of prostate cancer  
(8.6-fold in men ≤65 years). BRCA gene mutations, particularly in BRCA2, 
enhance the likelihood of developing PCa and have implications for disease 
prognosis and management [41]. BRCA2 and BRCA1’s roles in prostate tumori-
genesis are still unknown. The gene BRCA1 has been linked to an increased risk 
of sporadic prostate cancer. The relevance of BRCA1 and BRCA2 to male cancer 
has been extensively researched since families with these mutations demonstrate 
clustering of cancer in men. Both BRCA1 and BRCA2 are tumor suppressor genes 
that are inherited in an autosomal dominant, incomplete penetrance manner [42]. 
Although some studies have begun to assess the involvement of these genes in 
prostate cancer, the precise role of BRCA1 and BRCA2 in prostate cancer progres-
sion and progression has yet to be determined. BRCA1 is one of the co-regulators 
of the androgen receptor (AR), which regulates a signaling pathway important 
for prostate cancer progression and progression. BRCA2 was more common in 
castrate-resistant prostate cancer than primary prostate cancer, further inferring 
the invasive nature of prostate cancer in BRCA2 mutation carriers [43]. Some, like 
BRCA2, are beginning to show clinical promise in the treatment and screening 
of prostate cancer. Numerous studies have shown that the common BRCA1 and 
BRCA2 mutations found in breast and ovarian cancer families also increase the 
risk of prostate cancer in Ashkenazi Jewish populations [41–44]. The odds ratios 
range from 2.1 to 4.8 and principally reach statistical significance for BRCA2 but 
not BRCA1. Further, studies in various populations assist a role for BRCA2. RNase 
L (2′–5′ oligoadenylate-dependent ribonuclease L) (HPC1), located at chromo-
some 1q22; MSR1, with a linkage region on chromosome 8p; and ELAC2 (HPC2), 
on chromosome 17p11 are the most pertinent candidate genes for prostate cancer 
[45]. In prostate cancer, these three genes have been identified as inherited tumor 
suppressor genes. The key changes in the RNase L gene linked to prostate cancer 
include D541E, R462Q , and I97L missense mutations. R462Q and D541E are 
antonymous variations of RNase L that exhibit a decrease in enzymatic activity 
[46]. In hereditary situations, the R462Q or Arg462G ln variation is linked to an 
increased prostate cancer risk in the Finnish population, American Caucasians, 
and Japanese men. I97L is a missense mutation in the ankyrin domain’s third and 
seventh repeat sites. There is no clear link between this mutation and the risk of 
prostate cancer [47].
Hereditary prostate cancer 1 gene (HPC1) (1q24–25), CAPB (1p36), PCAP 
(1q42–43), HPC2 (17p12), HPC20 (20q13), and HPCX (Xq27–28) are the genes 
responsible for the advancement of sporadic and, in particular, familial prostate 
cancer. Certain regions in the MSR1 gene appear to play a role in prostate cancer. 
rs12718376, in the terminal 3= regions of gene MSR1, was characterized as linked to 
a heightened prostate cancer risk in the Caucasian population [48]. With HOXB13 
bearers, a subjective history of invasive cancer is strongly retained. The findings 
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of Beebe-Dimmer et al. show that the G84E mutation in the HOXB13 gene affects 
about 0.5 percent of people of European heritage, confirming previous claims that 
the mutation is linked to prostate cancer [49].
5. Alternate pathways of PC risk
5.1 PI3K/Akt signaling pathway
PI3K/Akt signaling pathway is one of the most well-known alternate pathways in 
prostate cancer. This pathway’s activation appears to be common in many aggres-
sive prostate tumors. Additionally, as prostate cancer develops toward a resistant, 
metastatic condition, the PI3K/Akt pathway is more frequently activated [43–45]. 
Cellular metabolism, tumor genesis, growth, proliferation, metastasis, and cyto-
skeletal remodeling are all controlled by this signaling system. The activation of 
growth and survival pathways is one way that the PI3K pathway might cause cancer.
Further, there is an involvement of the PI3k/Akt pathway in prostate cancer 
with modulation of DNA damage repair pathway [46]. Furthermore, the PI3K/Akt 
pathway is involved in modifying a more invasive phenotype in prostate cancer cells 
through modulating cholesterol ester production. Phosphatases such as phosphatase 
and tensing homolog gene (PTEN), PH and leucine-rich repeat protein phosphatase 
(PHLPP), cellular prostatic acid phosphatase, PP2A, and INPP4B activate the PI3K/
Akt pathway. The PI3K/Akt pathway has also been demonstrated to be important 
in the survival and proliferation of prostate cancer stem cells. The link between 
the PI3K/Akt and AR pathways has piqued researchers’ curiosity as a potential 
co-targeting method in prostate cancer. In various preclinical studies, reciprocal 
connections between these pathways have been demonstrated. These preclinical 
discoveries have aided the advancement of clinical trials including the combined 
inhibition of both the AR and the PI3k/Akt/mTOR pathways. With the invasive 
oncogenic properties of the PI3K/Akt pathway, there has been a lot of interest in 
using it as a biomarker to discriminate more significantly [48].
Although present research suggests that this pathway gives predictive informa-
tion, it is unclear whether it offers many significant advantages over currently 
employed clinical and pathologic indicators. However, there is continued interest in 
using this pathway as a predictive biomarker for newly targeted medicines of this 
pathway. Activation of the PI3K/Akt pathway is undoubtedly important in the inva-
sive character of many prostate tumors. As more individuals develop non-AR-driven 
tumors, this non-androgen receptor pathway may become increasingly relevant with 
the use of contemporary AR pathway inhibitors and combination therapy.
5.2 Vascular endothelial growth factor (VEGF)
In both healthy and pathological settings, vascular endothelial growth factor 
(VEGF) is widely recognized as a potent activator of angiogenesis. Most solid 
tumors, including prostate cancer, have strong evidence of it. Prostate cancer is 
aided by vascular endothelial growth factor (VEGF) and pigment epithelium-
derived factor (PEDF) [49]. Angiogenesis appears to play a significant role in 
prostate cancer, according to sufficient data. Secretion of protein factors such as the 
vascular endothelial growth factor (VEGF) is exuded by prostate cancer cells which 
are widely studied and known as the major angiogenic marker. Many variables 
control and regulate the VEGF pathway, including local environmental hypoxia and 
different hormones, growth factors, and cytokines.
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5.3 Epidermal growth factor receptor (EGFR)
The overexpression of EGFR (epidermal growth factor receptor) is associated 
with the progression of prostate cancer in the vast majority of cases, showing that 
this may play a mechanistic role. The first known member of the HER receptor 
family was the Epidermal growth factor receptor (EGFR or HER-1). After total 
prostatectomy, the risk of recurrence and succession to hormone resistance is 
associated with the expression of EGFR. One hundred percentages of metastases 
of hormone-refractory prostate cancers express EGFR, implying that this recep-
tor is a primary transduction pathway for tumor growth [50]. Only a few clinical 
trials using combos with anti-EGFR drugs have lately been conducted. Erlotinib is a 
reversible and orally active EGFR tyrosine kinase inhibitor that stops the cell cycle 
in the G1 phase. The preclinical results imply that combining additional targeted 
treatments with EGFR, particularly antiangiogenics, should be studied.
5.4 Single nucleotide polymorphisms (SNPs)
In addition, GWAS has identified more than 150 SNVs related to the advance-
ment of prostate cancer, but the clinical advantage of these findings remains 
skeptical.
5.4.1 8q24
The 8q24 polymorphisms have been implicated in various cancers. Overall, 
each of the 8q24 polymorphisms was individually correlated with prostate cancer 
risk. Substantial relations were also observed in an analysis by ethnicity, source of 
control, and quality score. Interestingly, the effect of rs1447295 on prostate cancer 
risk was observed among Caucasians and Asians, but not Africa-Americans. The 
effect of rs16901979 was more eminent among Africa-Americans than Asians [37]. 
Similarly, rs6983267 conferred a higher prostate cancer risk among Caucasians than 
Asians. Collaboratively, these 8q24 variants (s) may regulate prostate cancer risk in 
an ethnic-specific manner. 8q24 rs4242382-A polymorphism was associated with 
prostate cancer risk in Chinese men.
5.4.2 17q12 and 17q24
Gudmundsson and colleagues identified two prostate cancer susceptibility loci 
on chromosome 17q in a recent genome-wide association study. Precisely, there was 
an association of two intronic SNPs in the TCF2 gene (rs4430796 and rs7501939) 
at 17q12 and a third SNP (rs1859962) at 17q24 with the sporadic prostate cancer 
risk. The strongest evidence of prostate cancer association was observed in SNPs 
rs4430796 and rs7501939. Moreover, the results obtained by Levin et al., suggest that 
the increased risk associated with these SNPs is approximately doubled in individu-
als making them susceptible to develop the timely-onset disease. While the results 
for correlation of SNP rs1859962 at 17q24 were not statistically substantial, there was 
symbolic evidence that the “G” allele was over-transmitted to affected men [38–41].
5.4.3 HOXB13 gene
In the HOXB13 gene, an exotic modification named as G84E (rs138213197)  
has been identified according to the studies conducted in 2012, which has been 
categorized as the first major genetic variation linked with familial prostate cancer.  
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The function of HOXB13 in prostate cancer is not well recognized [43]. The 
HOXB13 protein is known to be critical in the embryonic development of the 
prostate gland and is expressed in normal prostate tissue toward adulthood. There 
is an indication that HOX genes may act as both, an oncogene and a tumor suppres-
sor gene in the prostate as well as other cancers. The carriers of the G84E mutation 
represent 0.5% of the total population and are found almost exclusively among 
patients of known European ancestry (Figures 1 and 2).
5.4.4 11q13
The prostate cancer susceptibility alleles on chromosome 11q13 have been 
identified by genome-wide association studies. Chung et al. reported the results 
of fine-mapping the region surrounding the most notable SNP, rs10896449, origi-
nally associated with prostate cancer risk in 11q13. Numerous locus models that 
included consequential SNPs consecutively identified that the second association of 
rs12793759 is independent of rs10896449 and remained significant [8].
5.4.5 JAZF1 gene
Chen et al. demonstrated that two loci (rs4242382 and rs10486567) are highly 
associated with familial multiple prostate cancer. A stronger effect of the risk allele 
Figure 1. 
Mechanism of action of HOXB13 gene.
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A at rs10486567 was observed in the presence of the risk allele A at rs4242382. 
The SNP rs10486567 at 7p15.2 was consistent with the genome-wide study. A three 
C2-H2-type zinc finger protein, which is a transcriptional repressor of NR2C2, a 
nuclear orphan receptor is encoded by the SNP rs10486567 located within intron 
2 of the JAZF1 gene on chromosome 7p15.2. This protein is highly expressed in 
prostate tissue and interacts with the androgen receptor [9].
5.4.6 11q12, 10q26 and 3p11.2
We have identified three new loci, 11q12, 10q26, and 3p11.2, that are associ-
ated with prostate cancer susceptibility at a genome-wide significance level in 
the Japanese population. These findings provide additional support for conduct-
ing GWAS for prostate cancer in diverse populations to identify risk loci for this 
genetically heterogeneous cancer. Akamatsu et al. showed that there are three new 
loci, 11q12, 10q26, and 3p11.2 that are associated with prostate cancer vulnerability 
at a genome-wide significance level in the Japanese population. These findings 
provide additional assistance for conducting Genome-wide association studies 
for prostate cancer in diverse populations to recognize risk loci for this genetically 
heterogeneous cancer. Further functional studies are required to understand the 
biological consequences of the newly recognized vulnerable loci in prostate cancer 
carcinogenesis [10].
For SNP rs5945572 A on Xp11 the findings were the same for cases with younger 
age at onset (≤65) or aggressive phenotype and the entire group. On the other 
hand, there was significantly higher frequency of rs721048 A, among individuals 
diagnosed with aggressive prostate cancer than among those with less aggressive 
disease. Both the Xp11 and the 2p15 variants are familiar and confer a moderate risk, 
resulting in an estimated 7% of individuals of European descent to prostate cancer 
risk. However, the cardinal causative biological perturbation associated with these 
variants remains to be illuminated. Certainly, subsequent studies have not been able 
to confirm numerous considerable gene regions that are recognized by association 
Figure 2. 
Mechanism of action of SRD5A gene.
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analysis and the strategies of identifying candidate genes have not worked effec-
tively. Regardless of this, the advances in genomic technologies and techniques of 
detection have enhanced the proficiency to study the cardinal genetics of prostate 
cancer risk. Still, no other biomarkers are used at the moment for the identification 
of prostate cancer. Regardless, numerous studies for finding alternative biomark-
ers are in process, such as PCA3 (prostate cancer antigen 3), TMPRSS2: ETS 
(transmembrane protease, serine 2: transcription factor ETS-related gene), GSTP1 
(glutathione-S-transferase enzyme), and C-reactive protein, but they still need to be 
examined in clinical trials [50–52].
A risk factor is anything that increases a person’s chance of developing cancer. 
Although risk factors often influence the chance to develop cancer, most of them 
do not directly or by themselves cause cancer. Some people with several known risk 
factors never develop cancer, while others with no known risk factors do [53]. In 
prostate cancer, it is normal to distinguish between epidemiologic endogenic factors 
(e.g., race, hormonal factors, genealogical information, age, etc.) and exogenic fac-
tors (e.g., sustenance, ecological factors, and lifestyle) which also include smoking, 
excess body fat accumulation.
6. Genetic and environmental risk factors
6.1 Age
One of the most important risk factors for prostate cancer is age. Between  
the ages of 55 and 74, a person’s risk of acquiring prostate cancer is estimated to 
be. The occurrence and mortality rates of prostate cancer are significantly  
linked to age, with the highest prevalence found in older men over 65 years of 
age [54].
6.2 Race/ethnicity
African-Americans have the highest prostate cancer risk, followed by whites, 
Hispanics, American Indians/Alaska Natives, and Asian/Pacific Islanders. 
According to the American Cancer Society, African-Americans have a death rate 
that is double that of white men. The risk of prostate cancer in Scandinavian males 
may also be higher. Historically, the occurrence rate in East Asia (Japan and China) 
has been low. However, when Chinese and Japanese men immigrate to the U.S., 
they have an elevated risk of developing prostate cancer when compared with their 
native populations [55].
6.3 Diet
The high intake of calories and fats in western diets is undoubtedly one of the 
primary causes of prostate cancer. Saturated fat, which is often ingested from 
animal sources, may be linked to the development of prostate cancer, however the 
link is small. Red meat is a key component of animal-fat consumption, and some 
research suggests red meat consumption has risk ratios. The biological causes for 
this link are still a mystery. Alpha-linolenic acid, an 18-carbon fatty acid found in 
meat and some vegetable oils, is significant because it is a necessary precursor for 
the creation of prostaglandins and leukotrienes. More research is needed to see 
if dietary substitution of fatty acids implicated in the prostaglandin production 
pathways affects prostate cancer development [56].
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There are more than 20 epidemiological studies that have evaluated the role of dairy 
food intake in prostate cancer. These studies are compatible with a positive association, 
unrelated to the contribution of dairy foods to total and saturated fat intake. Although 
β-carotene intake has not been related with prostate cancer risk, another crucial dietary 
carotenoid compound—lycopene—has become the priority of considerable notoriety. 
Lycopene, which is mostly absorbed through the ingestion of tomato-based foods, is 
the most important carotenoid in most Americans’ diets. Consuming either a lycopene-
rich diet or a β-carotene additive is thought to reduce the incidence of prostate cancer 
by about 40% [57]. Legumes, which include but are not limited to soy, have also been 
researched concerning to prostate cancer risk. So far, nothing has been corroborated 
by the findings. Green tea, another plant product that includes several polyphenolic 
chemicals with possible anti-carcinogenic qualities, is also being investigated.
6.4 Obesity
Obesity has been found to not affect the overall risk of prostate cancer, accord-
ing to numerous studies. Obese men, on the other hand, are more likely to develop 
more aggressive forms of prostate cancer.
6.5 Family history
Numerous investigations, including familial prostate cancer gatherings, twin 
studies, and illness incidence in young individuals, support the importance of 
genetic variables. Prostate cancer is classified into two types: familial and sporadic. 
Familial/genealogical prostatic disease is a malignancy that occurs in affected 
members of one family at an early age (55 years old). This type of cancer has at least 
one first-degree relative with prostate cancer [48–53]. However, in sporadic prostate 
cancer, the genetic material is damaged over time due to external environmental 
sensitivity. A family can be affected by this type of cancer if three generations are 
affected, three first-degree relatives are affected, or two relatives are affected before 
the age of 55. Both forms of cancer have different rates of occurrence. Familial/
genetic cancer has a rate of 15%, while sporadic carcinoma has a rate of 80 to 90%. 
A meta-analysis of several studies found that the cancer risk is higher for men who 
have a brother who has been diagnosed with cancer rather than a father. The most 
and that the genealogical risk is higher for early-onset disease [52].
7. Non-dietary environmental risk factors
7.1 Smoking
Smoke from burning tobacco is considered a carcinogen for many human malig-
nancies, both submissive and non-submissive. Regardless, determining its causal 
link with prostate cancer has been a lengthy procedure. Because tobacco smoke 
carcinogens work explicitly, producing DNA mutations, and indirectly, causing 
hormone metabolism alterations, the causal link with prostate cancer is biologically 
reasonable. Some researchers have discovered a link between smoking and specific 
genetic variants that are linked to an increased risk of prostate cancer [54].
7.2 Socio-economic factors
All social elements, including economic, lifestyle, scholastic, and intellectual 
aspects, do not appear to influence the risk of prostate cancer on their own. Despite 
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this, they are indirectly involved by influencing dietary factors, occupational 
exposure, and access to health systems, both for timely detection and appropriate 
treatment, and they are unquestionably involved by influencing dietary factors, 
occupational exposure, and acquisition to health systems [12–15].
7.3 Other genetic changes
Other genes that may support a heightened risk of developing prostate cancer 
include HPC1, HPC2, HPCX, CAPB, ATM, FANCA, HOXB13, and mismatch repair 
genes. None of these, however, has been proven to cause prostate cancer or to be 
specific to this illness. Researchers are working to find genes linked to an increased 
risk of prostate cancer, and they are always attempting to learn more about how 
specific genetic changes can influence the spread of prostate cancer [23].
7.4 Occupational risk factors
Prostate cancer is thought to be caused by a variety of occupational variables. 
Farmers/agricultural workers, chemicals (organochlorine insecticides), shift work, 
and flight personnel are also risk factors [45].
7.5 Insecticides/pesticides
The most often used pesticide/insecticide was lead arsenate. Its use was 
reduced, but not stopped, until 1988, due to later discoveries of its harmful health 
consequences. In the United States, however, the usage of lead arsenate has poi-
soned most of the farmed land. Many workers are expected to develop cancer as a 
result of its carcinogenic qualities. Most frequently used insecticides are organo-
chlorine pesticides, organophosphorus pesticides, carbamates, concerning to and 
triazines [51–56]. Ancestry is also important in the interplay between pesticide 
susceptibility and ancestry. When exposed to pesticides, a person with a family 
history of prostate cancer has a significantly increased risk of prostate cancer, 
which has been confirmed for carbamates, fonofos, chlorpyrifos, and phorate. 
Evidence is also presented that pesticide exposure causes cancer to become more 
aggressive.
7.6 Organochlorine pesticides
In Swedish and American research, rational results demonstrated a link between 
organochlorine pesticides and a significantly elevated incidence of prostate cancer. 
In a Swedish study, chlordane was shown to be the most dangerous organochlorine 
pesticide, whereas heptachlor, 2,4-dichlorophenoxyacetic acid (2,4-D), and lindane 
were found to be the most dangerous. Certain review articles support a bit that 
pesticides may elevate the prostate cancer risk minimally. The specific pesticide that 
is responsible for the increased risk is not yet discovered [57].
7.7 Shift work
Shift work is usually classified as work that is not done during the day. As a 
result, continual night shift work is classified as shift work. There is a strong link 
between shift work exposure and prostate cancer. Because of the various exposure 
conditions, the degree of variability is fairly significant. A meta-analysis conducted 
by Krstev et al. and prior meta-analyses provided evidence that shift employment, 
including night work, can raise the risk of prostate cancer [48].
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7.8 Flight personnel
A great number of researchers have looked into the risk of cancer in-flight crew 
members. Because flight crews frequently travel across multiple time zones, they 
are sometimes thought to be representatives for circadian rhythm disturbance. They 
are, nonetheless, subjected to carcinogenic ionizing cosmic radiation [57]. They are, 
nonetheless, subjected to carcinogenic ionizing cosmic radiation. Cancer risk might 
be increased as a result of several exposures. According to a meta-analysis undertaken 
by Krstev et al., pilots had a considerably increased risk of prostate cancer. It is dif-
ficult to explain the variation between the pilots and cabin crew by circadian rhythm 
disorder or cosmic radiation and could be due to unrestricted distraction [58]. The 
evidence implies that there may be a link between pilots and prostate cancer.
7.9 Farming
A farmer’s job entails a variety of responsibilities, including animal care, dealing 
with feed, seed, and animal waste, salvaging hay and other grains, driving tractors 
and other vehicles, operating various machines, and performing maintenance and 
repairs. As a result, they are exposed to organic and inorganic dust, pesticides, 
fungus, germs, viruses, lubricants, diesel exhaust, and welding fumes, and ultra-
violet light [49–53]. Due to a variety of exposures, numerous studies have suggested 
an increased prostate cancer risk in farmers compared to other occupations.
7.10 Screening
PSA (prostate-specific antigen) is a substance produced by the prostate gland. 
High PSA readings can indicate prostate cancer, prostatitis (a noncancerous illness), 
or an enlarged prostate gland. The prostate-specific antigen (PSA) test is the most 
widely used prostate cancer screening method. This is a straightforward blood test 
that determines the amount of PSA in your circulation. This test is usually the first 
step in any prostate cancer diagnosis. Nonetheless, PSA screening alone cannot 
determine whether cancer is present. The PSA test is also used to monitor the effects 
of treatment for prostate cancer, such as surgery, radiation, hormone therapy, and 
chemotherapy [55]. When a man undergoes treatment for prostate cancer, his PSA 
level will plunge significantly. Conventional screening with PSA is one of the tools 
the physician will use to measure if cancer has recurred. Biochemical recurrence 
occurs when PSA levels rise to a certain threshold following prostate cancer treat-
ment. This means that some cancer cells have managed to survive and are now 
releasing PSA. If this occurs, the doctor will schedule additional testing and suggest 
additional treatment options.
8. Prostate cancer treatment
8.1 Surgery for prostate cancer
A radical prostatectomy is the main type of surgery for prostate cancer. In this 
operation, the surgeon removes the complete prostate gland and additionally some 
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In the more conventional approach to prostatectomy, called an open prostatec-
tomy, the surgeon operates through a single long skin incision (cut) to eliminate 
the prostate and surrounding tissues whereas, in a laparoscopic prostatectomy, the 
surgeon makes numerous minor incisions and uses extraordinary long surgical tools 
to eliminate the prostate. The surgeon either holds the equipment straight away 
or uses a control panel to specifically move robotic arms that clasp the equipment 
[57]. This technique of prostatectomy has become more common in recent times. If 
done by experienced surgeons, the laparoscopic radical prostatectomy can provide 
outcomes analogous to the open approach.
8.1.1 Open prostatectomy
Open prostatectomy comprises Radical retropubic prostatectomy and Radical 
perineal prostatectomy.
8.1.1.1 Radical retropubic prostatectomy
For this open operation, the surgeon creates an incision in the lower abdomen, 
from the umbilicus down to the pubic bone. Either general anesthesia (asleep) or 
spinal or epidural anesthesia (drugging the lower half of the body) is given together 
with sedation during the surgery. If there is a plausible chance that cancer might 
have spread to surrounding lymph nodes (based on your PSA level, prostate biopsy 
results, and other conditions), the surgeon may also eliminate some of these lymph 
nodes at this time which is known as a pelvic lymph node dissection. The nodes are 
then dispatched to the laboratory to identify if they have cancer cells in them. If the 
cancer cells are found in any of the nodes, the surgeon might not proceed with the 
surgery [59]. This is because it is doubtful if cancer can be cured with surgery and 
eliminating the prostate could assist with severe side effects. After the prostate is 
eliminated, still under anesthesia, a catheter which is a thin, flexible tube will be 
put in the penis to help exude the bladder. The catheter will usually stay in place 
for 1 to 2 weeks until healed. After the catheter is removed, patients can urinate on 
their own [60].
8.1.1.2 Radical perineal prostatectomy
In this open operation, the surgeon makes an incision in the skin between the 
anus and scrotum (the perineum). This strategy is used less often because it is more 
plausible to lead to erection problems and because the surrounding lymph nodes 
cannot be eliminated. But it is usually a shorter operation and might be an alterna-
tive if erections are not concerned and there is no need for the lymph nodes to be 
removed. It also might be used if any other medical conditions make retropubic 
surgery dangerous. It can be just as remedial as the retro public approach if done 
accurately [57]. The perineal operation may cause less pain and an easier recupera-
tion than the retropubic prostatectomy. After the surgery, still under anesthesia, 
a catheter will be put in the penis to assist exude the bladder. The catheter usually 
stays in place for 1 to 2 weeks until healed. After the catheter is removed, patients 
can urinate on their own.
8.1.2 Laparoscopic prostatectomy
If treatment with laparoscopic surgery is taken under consideration, it is crucial 
to comprehend what is familiar and what is not yet familiar about this approach. 
The most significant factors are likely to be the aptitude and experience of the 
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surgeon. If it is decided that laparoscopic surgery is the right treatment, be sure to 
look for a surgeon with a lot of experience. Laparoscopic prostatectomy comprises 
Laparoscopic radical prostatectomy and Robotic-assisted laparoscopic radical 
prostatectomy [59].
8.1.2.1 Laparoscopic radical prostatectomy
For a laparoscopic radical prostatectomy (LRP), the surgeon inserts special long 
equipment through numerous small incisions in the abdominal wall to eliminate 
the prostate. One of the pieces of equipment has a small video camera on the end, 
which lets the surgeon see the interior of the body. Laparoscopic prostatectomy has 
some advantages over open radical prostatectomy, encompassing limited blood loss 
and pain, shorter hospital stays (usually no more than a day), rapid recovery times, 
and the catheter will need to remain in the bladder for less time [60]. The rates of 
major side effects from LRP, such as erection difficulties and discomfort holding 
urine (incontinence) seem to be about as identical as for open prostatectomies. 
Recovery of bladder control may be hindered slightly with this approach. However, 
more long-term studies are required to compare side effects and risks of recurrence. 
Between open prostatectomy and laparoscopic radical prostatectomy, the success of 
either technique seems to be determined primarily by the experience and aptitude 
of the surgeon [55].
8.1.2.2 Robotic-assisted laparoscopic radical prostatectomy
This technique is also known as robotic prostatectomy. In this technique, 
laparoscopic surgery is done using a robotic system. The surgeon settles down at a 
control panel in the operating room and robotic arms are moved to operate through 
numerous small incisions in the patient’s abdomen. Robotic prostatectomy has 
superiority over the open approach in terms of less pain, blood loss, and healing 
time. But with regards to the side effects, men are most concerned about urinary 
and/or erection difficulties [53]. There does not seem to be a discrepancy between 
robotic prostatectomy and other techniques. For the surgeon, the robotic system 
may provide more maneuverability and more accuracy when moving the equip-
ment than a conventional laparoscopic radical prostatectomy. Regardless, the most 
important factor in the accomplishment of either type of laparoscopic surgery is the 
surgeon’s experience and aptitude.
8.2 Risks of prostate surgery
The risks with any type of radical prostatectomy are much like those of any 
major surgery. Difficulties throughout or momentarily after the operation can 
encompass:
• Reactions to anesthesia
• Loss of blood from the surgery
• Blood clumps in the legs or lungs
• Injury to surrounding organs
• Infections at the site of surgery.
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8.3 Side effects of prostate surgery
The major possible side effects of radical prostatectomy include incontinence 
of urine i.e., being unable to control urine and erectile dysfunction i.e., impotence; 
problems getting or keeping erections. These side effects can also occur with other 
forms of prostate cancer treatment [57–59].
Incontinence of urine: not being able to control urine or having leakage or 
dribbling. Being incontinent can influence not only physically but emotionally and 
socially as well. Some of the major types of incontinence include:
1. Men who lack self-restraint of stress might leak urine when they cough, laugh, 
sneeze, or exercise. Lacking self-restraint of stress is the most popular after 
prostate surgery. It’s usually induced by trouble with the bladder sphincter 
valve. Prostate cancer treatments can damage this valve that keeps urine in the 
bladder or the nerves that keep the valve functioning.
2. Men who lack self-restraint of overflow have trouble emptying their bladder. 
They take a long time to urinate and have a dribbling stream with little force. 
This is usually inflicted by blockage or narrowing of the bladder opening by 
scar tissue.
3. Men who lack self-restraint of urge have an instant need to urinate. This 
happens when the bladder becomes too susceptible to stretching as it fills 
with urine.
4. Barely after surgery, men lost all proficiency to control their urine. This is 
called continuous incontinence.
9. Chemotherapy
Chemotherapy (chemo) utilizes anti-cancer drugs injected into a vein or given 
orally. These drugs travel through the bloodstream to reach cancer cells through-
out the body. Chemo is periodically used if prostate cancer has spread outside 
the prostate gland and hormone therapy has been proven futile. Contemporary 
research has also indicated that chemo might be beneficial if provided along with 
hormone therapy. Chemo is still not a conventional treatment for timely prostate 
cancer [54].
9.1 Chemo drugs in treatment of prostate cancer
Chemo drugs are typically used one at a time for prostate cancer. Some of the 
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Extensively, the first chemo drug given is docetaxel, in combination with the 
steroid drug prednisone. If this does not function or stops functioning, cabazitaxel 
is usually the following chemo drug attempted (Although there may be additional 
treatment options as well).
Docetaxel and cabazitaxel have been indicated to help men live longer, on 
average than former chemo drugs. They may slow cancer’s development and also 
decrease its symptoms, resulting in a better quality of life. However, chemo is very 
improbable to remedy prostate cancer. Other chemo drugs being researched for 
utilization in prostate cancer include carboplatin, oxaliplatin, and cisplatin [56–58].
Chemo drugs for prostate cancer are typically given intravenously (IV), as an 
infusion over a certain period and some drugs, such as estramustine, are given as 
a pill orally. Usually, a slightly larger and sturdier IV is required in the vein system 
to dispense chemo. They are known as central venous catheters (CVCs), central 
venous access devices (CVADs), or central lines. They are used to provide medi-
cines, blood products, nutrients, or fluids right into the blood and can also be used 
to take out blood for testing. Many different kinds of CVCs are available. The most 
common types are the port and the PICC line [55].
Doctors usually give chemo in cycles, with each period of treatment followed by 
a relaxation period to give some time to recuperate from the impact of the drugs. 
Cycles are more frequently 2 or 3 weeks long. The schedule differs depending on the 
drugs used. For example, with certain drugs, the chemo is provided only on the first 
day of the cycle. With other drugs, it is provided for a few days in succession or once 
a week. Then, at the verge of the cycle, there are repetitions of the chemo scheduled 
to begin the next cycle. The duration of medication for progressive prostate cancer 
is based on how well it is functioning and what side effects it causes [56–58].
9.2 Apparent side effects of chemotherapy
Chemo drugs invade cells that are dividing instantly, which is why they function 
against cancer cells. But various cells in the body, such as those in the bone marrow 
(where new blood cells are made), the lining of the mouth and intestines, and the 
hair follicles, also divide rapidly. These cells can also be influenced by chemo, which 
can lead to side effects. The side effects of chemo are determined by the kind and 
dose of drugs provided and for how long they are consumed [59]. Various common 
side effects can include:
• Loss of hair
• Mouth sores
• Anorexia
• Nausea and vomiting
• Diarrhea
• Heightened chance of infections (from experiencing inadequate white 
blood cells)
• Manageable bruising or bleeding (from experiencing inadequate blood 
platelets)
• Exhaustion (from experiencing inadequate red blood cells)
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These side effects are temporary and normally disappear once the treatment is 
finished. There are usually ways to reduce these side effects. For example, drugs can 
be provided to help intercept or decrease nausea and vomiting. Together with these 
risks, various side effects are observed more usual with particular chemo drugs. For 
example:
• Docetaxel and cabazitaxel occasionally cause drastic allergic reactions. 
Medicines are provided before each treatment to help preclude this. These 
drugs can also destruct nerves leading to a phenomenon known as peripheral 
neuropathy, which can cause numbness, tingling, or burning sensations in the 
hands or feet.
• Mitoxantrone can, very unusually, cause leukemia after several years.
• Estramustine conveys an intensified risk of blood clots.
If any side effects are noticed while getting chemo, report them to the cancer 
care team so that they can be treated quickly. In certain cases, the doses of the 
chemo drugs may need to be decreased or medication may need to be impeded or 
ceased to obstruct the effects from getting worse.
10. Chemoprevention
Chemoprevention, a prophylactic strategy that utilizes non-poisonous natural or 
artificial compounds to alter, impede, or avert cancer by targeting certain steps in 
the carcinogenic pathway, is gaining adhesion among health care practitioners. Soy 
isoflavones and curcumin, staples of the Asian diet, have demonstrated convincing 
results as practical factors for the chemoprevention of prostate cancer [60]. This 
is because of their proficiency to regulate various intracellular signaling pathways 
which comprise cellular proliferation, apoptosis, inflammation, and androgen 
receptor signaling. Contemporary information has disclosed that the DNA damage 
response (DDR) is one of the timeliest incidents in the multistep advancement of 
human skin cancers to aggressive malignancy. Soy isoflavones and curcumin stimu-
late the DDR, providing an alternative and justification for their clinical application 
in prostate cancer chemoprevention.
The prostate cancer risk can be ameliorated by approximately 30% by soy food 
consumption. Elevated soy consumption is correlated with localized prostate cancer 
reduction even among Japanese men with a significantly high soy intake concerning 
Caucasians. Moreover, a lower mortality rate from prostate cancer was correlated 
with soy consumption. The level of PSA decreases in prostate cancer patients simply 
because of the customary consumption of soy. Lately, it has been reported that the 
widespread presence of equal production, a potential risk factor for prostate cancer, 
is decreasing in the young generations of Korea and Japan [53–58].
Some of the important points to take into consideration are that chemopreven-
tion must be safe, sustain the quality of life, reduce the occurrence, consequence, 
and harshness of the disease and be economically feasible. Of all the drugs that have 
demonstrated greater scientific evidence in clinical trials, worth mentioning are 
inhibitors of the enzyme 5-α reductase, which converts testosterone into dihy-
drotestosterone and two isoforms exist, type 1 and type 2 exist for this.
Dutasteride is an influential inhibitor of 5-α reductase and is 45 times stronger 
than finasteride in hindering type 1 isoform and twice as strong on isoform 2. 
Undoubtedly, this is a guaranteeing drug in the prevention of prostate cancer in 
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the risk population [59]. Among the scores of biomarkers being studied, numerous 
markers and techniques deserve awareness because of the promising published 
data indicating that better prostate cancer screening methods will be available in 
the coming times that will maintain non-aggressiveness and acceptability for both 
patients and urologists in clinical practice.
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